Science Bulletin Urges AI Pathology Tools Show 4 Clinical Proof Points, Not Just Accuracy
Updated
Updated · EurekAlert · Jul 31
Science Bulletin Urges AI Pathology Tools Show 4 Clinical Proof Points, Not Just Accuracy
3 articles · Updated · EurekAlert · Jul 31
Summary
A new Science Bulletin Perspective says pathology AI should be judged on safe, transparent clinical use, not slide-reading accuracy alone.
Hospitals face rising case volumes, more complex biomarker testing and pressure for faster results, making computational pathology attractive for diagnosis, risk assessment and treatment planning.
The authors say useful systems must show what was measured, where evidence came from, how reliable the result is and whether more testing is needed, while fitting existing pathology workflows.
Real-world validation should track effects on turnaround time, diagnostic consistency, case prioritization, unnecessary testing, clinical decisions and implementation costs.
Near-term uses include biomarker prescreening and quantitative scoring, but the paper says AI is more likely to support pathologists than replace them.